COVID-19 Impact on Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size, Status and Forecast 2020-2026
![](/report_cover/6975/covid-19-impact-on-global-non-peptide-drugs-of-angiotensin-ii-receptor-antagonist-market-size-status-n-forecast-2020-2026_en.gif)
This report focuses on the global Non-Peptide Drugs of Angiotensin II Receptor Antagonist status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non-Peptide Drugs of Angiotensin II Receptor Antagonist development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
The key players covered in this study
- Pfizer
- Novartis
- Merck
- AstraZeneca
- Jhonson and Johnson
- Eli Lilly
- Sanofi
- Bristol-Myers Squibb
- Bayer
- GSK
- Teva Pharmaceutical
- Shenzhen Salubris Pharmaceuticals
- Sun Pharmaceutical
- Mylan
- Alembic Pharmaceuticals
- Lupin
- Aurobindo Pharma
- Amneal Pharmaceuticals
- Boehringer Ingelheim
- Valsartan
- Irbesartan
- Candesartan Cilexetil
- Eprosartan
- Irbesartan
- Telmisartan
- losartan
- Olmesartan Medoxomil
- Allisartan isoproxil
- High Blood Pressure
- Congestive Heart Failure
- Left Ventricular Hypertrophy
- Atherosclerosis
- Other
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global Non-Peptide Drugs of Angiotensin II Receptor Antagonist status, future forecast, growth opportunity, key market and key players.
- To present the Non-Peptide Drugs of Angiotensin II Receptor Antagonist development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue
1.4 Market Analysis by Type
1.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Valsartan
1.4.3 Irbesartan
1.4.4 Candesartan Cilexetil
1.4.5 Eprosartan
1.4.6 Irbesartan
1.4.7 Telmisartan
1.4.8 losartan
1.4.9 Olmesartan Medoxomil
1.4.10 Allisartan isoproxil
1.5 Market by Application
1.5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application: 2020 VS 2026
1.5.2 High Blood Pressure
1.5.3 Congestive Heart Failure
1.5.4 Left Ventricular Hypertrophy
1.5.5 Atherosclerosis
1.5.6 Other
1.6 Coronavirus Disease 2019 (Covid-19): Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry Impact
1.6.1 How the Covid-19 is Affecting the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry
1.6.1.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Non-Peptide Drugs of Angiotensin II Receptor Antagonist Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Perspective (2015-2026)
2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Growth Trends by Regions
2.2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Share by Regions (2015-2020)
2.2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Strategy
2.3.6 Primary Interviews with Key Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Market Size
3.1.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Revenue (2015-2020)
3.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Players (2015-2020)
3.1.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio
3.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2019
3.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players Head office and Area Served
3.4 Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Solution and Service
3.5 Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Type (2015-2020)
4.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Type (2021-2026)
5 NON-PEPTIDE DRUGS OF ANGIOTENSIN II RECEPTOR ANTAGONIST BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
5.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
6.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in North America (2019-2020)
6.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
6.4 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
7.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Europe (2019-2020)
7.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
7.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
8 CHINA
8.1 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
8.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in China (2019-2020)
8.3 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
8.4 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
9.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Japan (2019-2020)
9.3 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
9.4 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
10.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
10.4 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
11 INDIA
11.1 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in India (2019-2020)
11.3 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
11.4 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
12.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Central & South America (2019-2020)
12.3 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
12.4 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview and Its Total Revenue
13.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.1.4 Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview and Its Total Revenue
13.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.2.4 Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Merck
13.3.1 Merck Company Details
13.3.2 Merck Business Overview and Its Total Revenue
13.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.3.4 Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.3.5 Merck Recent Development
13.4 AstraZeneca
13.4.1 AstraZeneca Company Details
13.4.2 AstraZeneca Business Overview and Its Total Revenue
13.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.4.4 AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.4.5 AstraZeneca Recent Development
13.5 Jhonson and Johnson
13.5.1 Jhonson and Johnson Company Details
13.5.2 Jhonson and Johnson Business Overview and Its Total Revenue
13.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.5.4 Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.5.5 Jhonson and Johnson Recent Development
13.6 Eli Lilly
13.6.1 Eli Lilly Company Details
13.6.2 Eli Lilly Business Overview and Its Total Revenue
13.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.6.4 Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.6.5 Eli Lilly Recent Development
13.7 Sanofi
13.7.1 Sanofi Company Details
13.7.2 Sanofi Business Overview and Its Total Revenue
13.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.7.4 Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.7.5 Sanofi Recent Development
13.8 Bristol-Myers Squibb
13.8.1 Bristol-Myers Squibb Company Details
13.8.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
13.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.8.4 Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.8.5 Bristol-Myers Squibb Recent Development
13.9 Bayer
13.9.1 Bayer Company Details
13.9.2 Bayer Business Overview and Its Total Revenue
13.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.9.4 Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.9.5 Bayer Recent Development
13.10 GSK
13.10.1 GSK Company Details
13.10.2 GSK Business Overview and Its Total Revenue
13.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.10.4 GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.10.5 GSK Recent Development
13.11 Teva Pharmaceutical
10.11.1 Teva Pharmaceutical Company Details
10.11.2 Teva Pharmaceutical Business Overview and Its Total Revenue
10.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.11.4 Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.11.5 Teva Pharmaceutical Recent Development
13.12 Shenzhen Salubris Pharmaceuticals
10.12.1 Shenzhen Salubris Pharmaceuticals Company Details
10.12.2 Shenzhen Salubris Pharmaceuticals Business Overview and Its Total Revenue
10.12.3 Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.12.4 Shenzhen Salubris Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.12.5 Shenzhen Salubris Pharmaceuticals Recent Development
13.13 Sun Pharmaceutical
10.13.1 Sun Pharmaceutical Company Details
10.13.2 Sun Pharmaceutical Business Overview and Its Total Revenue
10.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.13.4 Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.13.5 Sun Pharmaceutical Recent Development
13.14 Mylan
10.14.1 Mylan Company Details
10.14.2 Mylan Business Overview and Its Total Revenue
10.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.14.4 Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.14.5 Mylan Recent Development
13.15 Alembic Pharmaceuticals
10.15.1 Alembic Pharmaceuticals Company Details
10.15.2 Alembic Pharmaceuticals Business Overview and Its Total Revenue
10.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.15.4 Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.15.5 Alembic Pharmaceuticals Recent Development
13.16 Lupin
10.16.1 Lupin Company Details
10.16.2 Lupin Business Overview and Its Total Revenue
10.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.16.4 Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.16.5 Lupin Recent Development
13.17 Aurobindo Pharma
10.17.1 Aurobindo Pharma Company Details
10.17.2 Aurobindo Pharma Business Overview and Its Total Revenue
10.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.17.4 Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.17.5 Aurobindo Pharma Recent Development
13.18 Amneal Pharmaceuticals
10.18.1 Amneal Pharmaceuticals Company Details
10.18.2 Amneal Pharmaceuticals Business Overview and Its Total Revenue
10.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.18.4 Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.18.5 Amneal Pharmaceuticals Recent Development
13.19 Boehringer Ingelheim
10.19.1 Boehringer Ingelheim Company Details
10.19.2 Boehringer Ingelheim Business Overview and Its Total Revenue
10.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.19.4 Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.19.5 Boehringer Ingelheim Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue
1.4 Market Analysis by Type
1.4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Valsartan
1.4.3 Irbesartan
1.4.4 Candesartan Cilexetil
1.4.5 Eprosartan
1.4.6 Irbesartan
1.4.7 Telmisartan
1.4.8 losartan
1.4.9 Olmesartan Medoxomil
1.4.10 Allisartan isoproxil
1.5 Market by Application
1.5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application: 2020 VS 2026
1.5.2 High Blood Pressure
1.5.3 Congestive Heart Failure
1.5.4 Left Ventricular Hypertrophy
1.5.5 Atherosclerosis
1.5.6 Other
1.6 Coronavirus Disease 2019 (Covid-19): Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry Impact
1.6.1 How the Covid-19 is Affecting the Non-Peptide Drugs of Angiotensin II Receptor Antagonist Industry
1.6.1.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Non-Peptide Drugs of Angiotensin II Receptor Antagonist Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Perspective (2015-2026)
2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Growth Trends by Regions
2.2.1 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Share by Regions (2015-2020)
2.2.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Strategy
2.3.6 Primary Interviews with Key Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Market Size
3.1.1 Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Revenue (2015-2020)
3.1.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Players (2015-2020)
3.1.3 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio
3.2.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2019
3.3 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players Head office and Area Served
3.4 Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Solution and Service
3.5 Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Historic Market Size by Type (2015-2020)
4.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Type (2021-2026)
5 NON-PEPTIDE DRUGS OF ANGIOTENSIN II RECEPTOR ANTAGONIST BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
5.2 Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
6.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in North America (2019-2020)
6.3 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
6.4 North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
7.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Europe (2019-2020)
7.3 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
7.4 Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
8 CHINA
8.1 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
8.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in China (2019-2020)
8.3 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
8.4 China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
9.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Japan (2019-2020)
9.3 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
9.4 Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
10.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
10.4 Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
11 INDIA
11.1 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
11.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in India (2019-2020)
11.3 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
11.4 India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size (2015-2020)
12.2 Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Players in Central & South America (2019-2020)
12.3 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020)
12.4 Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview and Its Total Revenue
13.1.3 Pfizer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.1.4 Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview and Its Total Revenue
13.2.3 Novartis Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.2.4 Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Merck
13.3.1 Merck Company Details
13.3.2 Merck Business Overview and Its Total Revenue
13.3.3 Merck Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.3.4 Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.3.5 Merck Recent Development
13.4 AstraZeneca
13.4.1 AstraZeneca Company Details
13.4.2 AstraZeneca Business Overview and Its Total Revenue
13.4.3 AstraZeneca Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.4.4 AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.4.5 AstraZeneca Recent Development
13.5 Jhonson and Johnson
13.5.1 Jhonson and Johnson Company Details
13.5.2 Jhonson and Johnson Business Overview and Its Total Revenue
13.5.3 Jhonson and Johnson Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.5.4 Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.5.5 Jhonson and Johnson Recent Development
13.6 Eli Lilly
13.6.1 Eli Lilly Company Details
13.6.2 Eli Lilly Business Overview and Its Total Revenue
13.6.3 Eli Lilly Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.6.4 Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.6.5 Eli Lilly Recent Development
13.7 Sanofi
13.7.1 Sanofi Company Details
13.7.2 Sanofi Business Overview and Its Total Revenue
13.7.3 Sanofi Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.7.4 Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.7.5 Sanofi Recent Development
13.8 Bristol-Myers Squibb
13.8.1 Bristol-Myers Squibb Company Details
13.8.2 Bristol-Myers Squibb Business Overview and Its Total Revenue
13.8.3 Bristol-Myers Squibb Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.8.4 Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.8.5 Bristol-Myers Squibb Recent Development
13.9 Bayer
13.9.1 Bayer Company Details
13.9.2 Bayer Business Overview and Its Total Revenue
13.9.3 Bayer Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.9.4 Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.9.5 Bayer Recent Development
13.10 GSK
13.10.1 GSK Company Details
13.10.2 GSK Business Overview and Its Total Revenue
13.10.3 GSK Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
13.10.4 GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
13.10.5 GSK Recent Development
13.11 Teva Pharmaceutical
10.11.1 Teva Pharmaceutical Company Details
10.11.2 Teva Pharmaceutical Business Overview and Its Total Revenue
10.11.3 Teva Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.11.4 Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.11.5 Teva Pharmaceutical Recent Development
13.12 Shenzhen Salubris Pharmaceuticals
10.12.1 Shenzhen Salubris Pharmaceuticals Company Details
10.12.2 Shenzhen Salubris Pharmaceuticals Business Overview and Its Total Revenue
10.12.3 Shenzhen Salubris Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.12.4 Shenzhen Salubris Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.12.5 Shenzhen Salubris Pharmaceuticals Recent Development
13.13 Sun Pharmaceutical
10.13.1 Sun Pharmaceutical Company Details
10.13.2 Sun Pharmaceutical Business Overview and Its Total Revenue
10.13.3 Sun Pharmaceutical Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.13.4 Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.13.5 Sun Pharmaceutical Recent Development
13.14 Mylan
10.14.1 Mylan Company Details
10.14.2 Mylan Business Overview and Its Total Revenue
10.14.3 Mylan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.14.4 Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.14.5 Mylan Recent Development
13.15 Alembic Pharmaceuticals
10.15.1 Alembic Pharmaceuticals Company Details
10.15.2 Alembic Pharmaceuticals Business Overview and Its Total Revenue
10.15.3 Alembic Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.15.4 Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.15.5 Alembic Pharmaceuticals Recent Development
13.16 Lupin
10.16.1 Lupin Company Details
10.16.2 Lupin Business Overview and Its Total Revenue
10.16.3 Lupin Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.16.4 Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.16.5 Lupin Recent Development
13.17 Aurobindo Pharma
10.17.1 Aurobindo Pharma Company Details
10.17.2 Aurobindo Pharma Business Overview and Its Total Revenue
10.17.3 Aurobindo Pharma Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.17.4 Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.17.5 Aurobindo Pharma Recent Development
13.18 Amneal Pharmaceuticals
10.18.1 Amneal Pharmaceuticals Company Details
10.18.2 Amneal Pharmaceuticals Business Overview and Its Total Revenue
10.18.3 Amneal Pharmaceuticals Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.18.4 Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.18.5 Amneal Pharmaceuticals Recent Development
13.19 Boehringer Ingelheim
10.19.1 Boehringer Ingelheim Company Details
10.19.2 Boehringer Ingelheim Business Overview and Its Total Revenue
10.19.3 Boehringer Ingelheim Non-Peptide Drugs of Angiotensin II Receptor Antagonist Introduction
10.19.4 Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
10.19.5 Boehringer Ingelheim Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Market Segments
Table 2. Key Players Covered: Ranking by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue
Table 3. Ranking of Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Valsartan
Table 6. Key Players of Irbesartan
Table 7. Key Players of Candesartan Cilexetil
Table 8. Key Players of Eprosartan
Table 9. Key Players of Irbesartan
Table 10. Key Players of Telmisartan
Table 11. Key Players of losartan
Table 12. Key Players of Olmesartan Medoxomil
Table 13. Key Players of Allisartan isoproxil
Table 14. COVID-19 Impact Global Market: (Four Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast Scenarios)
Table 15. Opportunities and Trends for Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players in the COVID-19 Landscape
Table 16. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 17. Key Regions/Countries Measures against Covid-19 Impact
Table 18. Proposal for Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players to Combat Covid-19 Impact
Table 19. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 20. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions (US$ Million): 2020 VS 2026
Table 21. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions (2015-2020) (US$ Million)
Table 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions (2015-2020)
Table 23. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 24. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions (2021-2026)
Table 25. Market Top Trends
Table 26. Key Drivers: Impact Analysis
Table 27. Key Challenges
Table 28. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Strategy
Table 29. Main Points Interviewed from Key Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players
Table 30. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Players (2015-2020) (Million US$)
Table 31. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Players (2015-2020)
Table 32. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2019)
Table 33. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Players Market Concentration Ratio (CR5 and HHI)
Table 34. Key Players Headquarters and Area Served
Table 35. Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Solution and Service
Table 36. Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
Table 37. Mergers & Acquisitions, Expansion Plans
Table 38. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 39. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Type (2015-2020)
Table 40. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Type (2021-2026)
Table 41. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Application (2015-2020)
Table 42. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 43. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Application (2021-2026)
Table 44. North America Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 45. North America Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 46. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 47. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 48. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 49. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 50. Europe Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 51. Europe Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 52. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 53. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 54. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 55. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 56. China Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 57. China Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 58. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 59. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 60. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 61. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 62. Japan Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 63. Japan Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 64. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 65. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 66. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 67. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 68. Southeast Asia Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 69. Southeast Asia Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 70. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 71. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 72. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 73. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 74. India Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 75. India Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 76. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 77. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 78. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 79. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 80. Central & South America Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 81. Central & South America Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 82. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 83. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 84. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 85. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 86. Pfizer Company Details
Table 87. Pfizer Business Overview
Table 88. Pfizer Product
Table 89. Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 90. Pfizer Recent Development
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Product
Table 94. Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 95. Novartis Recent Development
Table 96. Merck Company Details
Table 97. Merck Business Overview
Table 98. Merck Product
Table 99. Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 100. Merck Recent Development
Table 101. AstraZeneca Company Details
Table 102. AstraZeneca Business Overview
Table 103. AstraZeneca Product
Table 104. AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 105. AstraZeneca Recent Development
Table 106. Jhonson and Johnson Company Details
Table 107. Jhonson and Johnson Business Overview
Table 108. Jhonson and Johnson Product
Table 109. Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 110. Jhonson and Johnson Recent Development
Table 111. Eli Lilly Company Details
Table 112. Eli Lilly Business Overview
Table 113. Eli Lilly Product
Table 114. Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 115. Eli Lilly Recent Development
Table 116. Sanofi Company Details
Table 117. Sanofi Business Overview
Table 118. Sanofi Product
Table 119. Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 120. Sanofi Recent Development
Table 121. Bristol-Myers Squibb Business Overview
Table 122. Bristol-Myers Squibb Product
Table 123. Bristol-Myers Squibb Company Details
Table 124. Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 125. Bristol-Myers Squibb Recent Development
Table 126. Bayer Company Details
Table 127. Bayer Business Overview
Table 128. Bayer Product
Table 129. Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 130. Bayer Recent Development
Table 131. GSK Company Details
Table 132. GSK Business Overview
Table 133. GSK Product
Table 134. GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 135. GSK Recent Development
Table 136. Teva Pharmaceutical Company Details
Table 137. Teva Pharmaceutical Business Overview
Table 138. Teva Pharmaceutical Product
Table 139. Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 140. Teva Pharmaceutical Recent Development
Table 141. Shenzhen Salubris Pharmaceuticals Company Details
Table 142. Shenzhen Salubris Pharmaceuticals Business Overview
Table 143. Shenzhen Salubris Pharmaceuticals Product
Table 144. Shenzhen Salubris Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 145. Shenzhen Salubris Pharmaceuticals Recent Development
Table 146. Sun Pharmaceutical Company Details
Table 147. Sun Pharmaceutical Business Overview
Table 148. Sun Pharmaceutical Product
Table 149. Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 150. Sun Pharmaceutical Recent Development
Table 151. Mylan Company Details
Table 152. Mylan Business Overview
Table 153. Mylan Product
Table 154. Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 155. Mylan Recent Development
Table 156. Alembic Pharmaceuticals Company Details
Table 157. Alembic Pharmaceuticals Business Overview
Table 158. Alembic Pharmaceuticals Product
Table 159. Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 160. Alembic Pharmaceuticals Recent Development
Table 161. Lupin Company Details
Table 162. Lupin Business Overview
Table 163. Lupin Product
Table 164. Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 165. Lupin Recent Development
Table 166. Aurobindo Pharma Company Details
Table 167. Aurobindo Pharma Business Overview
Table 168. Aurobindo Pharma Product
Table 169. Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 170. Aurobindo Pharma Recent Development
Table 171. Amneal Pharmaceuticals Company Details
Table 172. Amneal Pharmaceuticals Business Overview
Table 173. Amneal Pharmaceuticals Product
Table 174. Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 175. Amneal Pharmaceuticals Recent Development
Table 176. Boehringer Ingelheim Company Details
Table 177. Boehringer Ingelheim Business Overview
Table 178. Boehringer Ingelheim Product
Table 179. Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 180. Boehringer Ingelheim Recent Development
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources
Table 1. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Key Market Segments
Table 2. Key Players Covered: Ranking by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue
Table 3. Ranking of Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Valsartan
Table 6. Key Players of Irbesartan
Table 7. Key Players of Candesartan Cilexetil
Table 8. Key Players of Eprosartan
Table 9. Key Players of Irbesartan
Table 10. Key Players of Telmisartan
Table 11. Key Players of losartan
Table 12. Key Players of Olmesartan Medoxomil
Table 13. Key Players of Allisartan isoproxil
Table 14. COVID-19 Impact Global Market: (Four Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Forecast Scenarios)
Table 15. Opportunities and Trends for Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players in the COVID-19 Landscape
Table 16. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 17. Key Regions/Countries Measures against Covid-19 Impact
Table 18. Proposal for Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players to Combat Covid-19 Impact
Table 19. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 20. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions (US$ Million): 2020 VS 2026
Table 21. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Regions (2015-2020) (US$ Million)
Table 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions (2015-2020)
Table 23. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 24. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions (2021-2026)
Table 25. Market Top Trends
Table 26. Key Drivers: Impact Analysis
Table 27. Key Challenges
Table 28. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Growth Strategy
Table 29. Main Points Interviewed from Key Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players
Table 30. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue by Players (2015-2020) (Million US$)
Table 31. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Players (2015-2020)
Table 32. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2019)
Table 33. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist by Players Market Concentration Ratio (CR5 and HHI)
Table 34. Key Players Headquarters and Area Served
Table 35. Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Product Solution and Service
Table 36. Date of Enter into Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market
Table 37. Mergers & Acquisitions, Expansion Plans
Table 38. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 39. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Type (2015-2020)
Table 40. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue Market Share by Type (2021-2026)
Table 41. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Application (2015-2020)
Table 42. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 43. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size Share by Application (2021-2026)
Table 44. North America Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 45. North America Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 46. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 47. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 48. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 49. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 50. Europe Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 51. Europe Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 52. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 53. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 54. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 55. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 56. China Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 57. China Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 58. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 59. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 60. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 61. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 62. Japan Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 63. Japan Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 64. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 65. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 66. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 67. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 68. Southeast Asia Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 69. Southeast Asia Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 70. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 71. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 72. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 73. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 74. India Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 75. India Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 76. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 77. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 78. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 79. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 80. Central & South America Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue (2019-2020) (Million US$)
Table 81. Central & South America Key Players Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share (2019-2020)
Table 82. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Type (2015-2020) (Million US$)
Table 83. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type (2015-2020)
Table 84. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size by Application (2015-2020) (Million US$)
Table 85. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application (2015-2020)
Table 86. Pfizer Company Details
Table 87. Pfizer Business Overview
Table 88. Pfizer Product
Table 89. Pfizer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 90. Pfizer Recent Development
Table 91. Novartis Company Details
Table 92. Novartis Business Overview
Table 93. Novartis Product
Table 94. Novartis Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 95. Novartis Recent Development
Table 96. Merck Company Details
Table 97. Merck Business Overview
Table 98. Merck Product
Table 99. Merck Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 100. Merck Recent Development
Table 101. AstraZeneca Company Details
Table 102. AstraZeneca Business Overview
Table 103. AstraZeneca Product
Table 104. AstraZeneca Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 105. AstraZeneca Recent Development
Table 106. Jhonson and Johnson Company Details
Table 107. Jhonson and Johnson Business Overview
Table 108. Jhonson and Johnson Product
Table 109. Jhonson and Johnson Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 110. Jhonson and Johnson Recent Development
Table 111. Eli Lilly Company Details
Table 112. Eli Lilly Business Overview
Table 113. Eli Lilly Product
Table 114. Eli Lilly Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 115. Eli Lilly Recent Development
Table 116. Sanofi Company Details
Table 117. Sanofi Business Overview
Table 118. Sanofi Product
Table 119. Sanofi Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 120. Sanofi Recent Development
Table 121. Bristol-Myers Squibb Business Overview
Table 122. Bristol-Myers Squibb Product
Table 123. Bristol-Myers Squibb Company Details
Table 124. Bristol-Myers Squibb Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 125. Bristol-Myers Squibb Recent Development
Table 126. Bayer Company Details
Table 127. Bayer Business Overview
Table 128. Bayer Product
Table 129. Bayer Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 130. Bayer Recent Development
Table 131. GSK Company Details
Table 132. GSK Business Overview
Table 133. GSK Product
Table 134. GSK Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 135. GSK Recent Development
Table 136. Teva Pharmaceutical Company Details
Table 137. Teva Pharmaceutical Business Overview
Table 138. Teva Pharmaceutical Product
Table 139. Teva Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 140. Teva Pharmaceutical Recent Development
Table 141. Shenzhen Salubris Pharmaceuticals Company Details
Table 142. Shenzhen Salubris Pharmaceuticals Business Overview
Table 143. Shenzhen Salubris Pharmaceuticals Product
Table 144. Shenzhen Salubris Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 145. Shenzhen Salubris Pharmaceuticals Recent Development
Table 146. Sun Pharmaceutical Company Details
Table 147. Sun Pharmaceutical Business Overview
Table 148. Sun Pharmaceutical Product
Table 149. Sun Pharmaceutical Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 150. Sun Pharmaceutical Recent Development
Table 151. Mylan Company Details
Table 152. Mylan Business Overview
Table 153. Mylan Product
Table 154. Mylan Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 155. Mylan Recent Development
Table 156. Alembic Pharmaceuticals Company Details
Table 157. Alembic Pharmaceuticals Business Overview
Table 158. Alembic Pharmaceuticals Product
Table 159. Alembic Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 160. Alembic Pharmaceuticals Recent Development
Table 161. Lupin Company Details
Table 162. Lupin Business Overview
Table 163. Lupin Product
Table 164. Lupin Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 165. Lupin Recent Development
Table 166. Aurobindo Pharma Company Details
Table 167. Aurobindo Pharma Business Overview
Table 168. Aurobindo Pharma Product
Table 169. Aurobindo Pharma Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 170. Aurobindo Pharma Recent Development
Table 171. Amneal Pharmaceuticals Company Details
Table 172. Amneal Pharmaceuticals Business Overview
Table 173. Amneal Pharmaceuticals Product
Table 174. Amneal Pharmaceuticals Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 175. Amneal Pharmaceuticals Recent Development
Table 176. Boehringer Ingelheim Company Details
Table 177. Boehringer Ingelheim Business Overview
Table 178. Boehringer Ingelheim Product
Table 179. Boehringer Ingelheim Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020) (Million US$)
Table 180. Boehringer Ingelheim Recent Development
Table 181. Research Programs/Design for This Report
Table 182. Key Data Information from Secondary Sources
Table 183. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type: 2020 VS 2026
Figure 2. Valsartan Features
Figure 3. Irbesartan Features
Figure 4. Candesartan Cilexetil Features
Figure 5. Eprosartan Features
Figure 6. Irbesartan Features
Figure 7. Telmisartan Features
Figure 8. losartan Features
Figure 9. Olmesartan Medoxomil Features
Figure 10. Allisartan isoproxil Features
Figure 11. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application: 2020 VS 2026
Figure 12. High Blood Pressure Case Studies
Figure 13. Congestive Heart Failure Case Studies
Figure 14. Left Ventricular Hypertrophy Case Studies
Figure 15. Atherosclerosis Case Studies
Figure 16. Other Case Studies
Figure 17. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Report Years Considered
Figure 18. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth 2015-2026 (US$ Million)
Figure 19. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions: 2020 VS 2026
Figure 20. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions (2021-2026)
Figure 21. Porter's Five Forces Analysis
Figure 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Players in 2019
Figure 23. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2019
Figure 24. The Top 10 and 5 Players Market Share by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2019
Figure 25. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 31. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 32. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Pfizer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 34. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Novartis Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 36. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Merck Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 38. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. AstraZeneca Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 40. Jhonson and Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Jhonson and Johnson Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 42. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Eli Lilly Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 44. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Sanofi Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 46. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Bristol-Myers Squibb Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 48. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Bayer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 50. GSK Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. GSK Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 52. Teva Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Teva Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 54. Shenzhen Salubris Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Shenzhen Salubris Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 56. Sun Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Sun Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 58. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Mylan Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 60. Alembic Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Alembic Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 62. Lupin Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Lupin Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 64. Aurobindo Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Aurobindo Pharma Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 66. Amneal Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Amneal Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 68. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 69. Boehringer Ingelheim Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Figure 1. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Type: 2020 VS 2026
Figure 2. Valsartan Features
Figure 3. Irbesartan Features
Figure 4. Candesartan Cilexetil Features
Figure 5. Eprosartan Features
Figure 6. Irbesartan Features
Figure 7. Telmisartan Features
Figure 8. losartan Features
Figure 9. Olmesartan Medoxomil Features
Figure 10. Allisartan isoproxil Features
Figure 11. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Application: 2020 VS 2026
Figure 12. High Blood Pressure Case Studies
Figure 13. Congestive Heart Failure Case Studies
Figure 14. Left Ventricular Hypertrophy Case Studies
Figure 15. Atherosclerosis Case Studies
Figure 16. Other Case Studies
Figure 17. Non-Peptide Drugs of Angiotensin II Receptor Antagonist Report Years Considered
Figure 18. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth 2015-2026 (US$ Million)
Figure 19. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions: 2020 VS 2026
Figure 20. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Regions (2021-2026)
Figure 21. Porter's Five Forces Analysis
Figure 22. Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Share by Players in 2019
Figure 23. Global Top Non-Peptide Drugs of Angiotensin II Receptor Antagonist Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Peptide Drugs of Angiotensin II Receptor Antagonist as of 2019
Figure 24. The Top 10 and 5 Players Market Share by Non-Peptide Drugs of Angiotensin II Receptor Antagonist Revenue in 2019
Figure 25. North America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Europe Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. China Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Japan Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Southeast Asia Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 30. India Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 31. Central & South America Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Size YoY Growth (2015-2020) (Million US$)
Figure 32. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 33. Pfizer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 34. Novartis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 35. Novartis Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 36. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 37. Merck Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 38. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 39. AstraZeneca Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 40. Jhonson and Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 41. Jhonson and Johnson Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 42. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 43. Eli Lilly Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 44. Sanofi Total Revenue (US$ Million): 2019 Compared with 2018
Figure 45. Sanofi Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 46. Bristol-Myers Squibb Total Revenue (US$ Million): 2019 Compared with 2018
Figure 47. Bristol-Myers Squibb Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 48. Bayer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 49. Bayer Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 50. GSK Total Revenue (US$ Million): 2019 Compared with 2018
Figure 51. GSK Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 52. Teva Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 53. Teva Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 54. Shenzhen Salubris Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 55. Shenzhen Salubris Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 56. Sun Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 57. Sun Pharmaceutical Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 58. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 59. Mylan Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 60. Alembic Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 61. Alembic Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 62. Lupin Total Revenue (US$ Million): 2019 Compared with 2018
Figure 63. Lupin Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 64. Aurobindo Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 65. Aurobindo Pharma Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 66. Amneal Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 67. Amneal Pharmaceuticals Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 68. Boehringer Ingelheim Total Revenue (US$ Million): 2019 Compared with 2018
Figure 69. Boehringer Ingelheim Revenue Growth Rate in Non-Peptide Drugs of Angiotensin II Receptor Antagonist Business (2015-2020)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed